TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total MVSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of ALS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fast-track recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weight Transfer (WTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loading during double support (LOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Timing Factor (MTF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance with treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: cost‐benefit ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in soreness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: learning performance in head and neck anatomy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptance of illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family conflict
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: risk of non-spine fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Drug resistance gene mutation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary 8‐iso‐PGF(2alpha) excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 11‐dehydro‐TXB(2) excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in response assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetics of response and relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment of reversal learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step length symmetry aftereffects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overground gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overground step length asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in active inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in chronic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sexual dysfunction incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall dandruff score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global self‐assessment of efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma antioxidant capacity (TEAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aesthetic evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: daily peak expiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin iAUC (0-60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GLP-1 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: birth weight of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma α‐ and β‐carotene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma α‐, δ‐ and γ‐tocotrienol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bacterial colonization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PCSA of the PF muscle group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: T2 change of the MG, LG, or Sol muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Size of the late-phase reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total eosinophils (MBP+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activated eosinophils (EG2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scandinavian Stroke Study Group scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel Index ratings improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall local recurrence-free survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: 7-day abstinence rate
Endpoint domain: Mortality/survival
Primary endpoint: quit rates
Endpoint domain: Mortality/survival
Primary endpoint: interval to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom score after 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: PFD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in circulating blasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities (gastrointestinal, fatigue, transaminitis, tumor lysis syndrome)
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in disease-specific health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Somatic menopausal symptoms relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteinizing hormone suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SF36 (Physical Component Summary)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF36 (Mental Component Summary)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lid-parallel conjunctival folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma renin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deterioration in HRQoL and lung cancer symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of resin tags
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean morning PEF expressed as percent predicted (PEF-PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIST total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPV value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in training
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: slower reaction times on the Stroop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher reaction time variability on the Go/No-Go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased P300 amplitude on event-related potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the glycemic response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Systolic Velocity (PSV) in the central retinal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: End Diastolic Velocity (EDV) in the central retinal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Resistive Index (RI) in the central retinal artery and ophthalmic artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Recurrent atrial fibrillation (AF)
Endpoint domain: Mortality/survival
Primary endpoint: Simulator Joint Council on Thoracic Surgery Education scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fulcrum-bending correction index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sagittal profile correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congruence on patient EOL treatment goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AGE-DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice of health behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived uncertainty
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pain score after immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal lavage histamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of nausea and vomiting 12 hours after the operation
Endpoint domain: Adverse events/effects
Primary endpoint: Time for the first anal exsufflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ease of evoking a local twitch response (LTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major or clinically relevant non-major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Mental Health-Related Quality of Life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical Health-Related Quality of Life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BMI of ≥85th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall skin cancer incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Non-melanoma skin cancer (NMSC) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Basal cell carcinoma (BCC) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in PSE syndrome test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting total and LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve of insulin response to the test meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance of appetite
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total plasma clearance of frusemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fever as an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: unexplained falls
Endpoint domain: Adverse events/effects
Primary endpoint: all-cause falls
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in GCF volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of proinflammatory cytokines in GCF and PICF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Four-month TTF rate
Endpoint domain: Mortality/survival
Primary endpoint: Objective response duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VVP incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TVL measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in nutrition knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Taste ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Choice and consumption of vegetables
Endpoint domain: Life impact
Endpoint subdomain: Dietary habits
Primary endpoint: Mean Relative Clinical Attachment Level (RCAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: personal stigma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: three-year risk of ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 CRP remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uterine hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Additional uterine hemostatic sutures required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Endometritis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of MPR measurements for determining T-stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of posterolateral lumbar fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient anxiety reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vein quality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of KC and REFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portmann scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pain scores at 6 hours after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in the number of narcotic pills taken at 6 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inhibitory control of behavioural responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to symptom relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to symptom progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in NDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in FSST scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SLBT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numeric rating pain scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spinal performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily endothelial cell (EC) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic and diastolic blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurological and functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean time of ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial response and stable disease rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cetuximab trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ELF exposures of ceftazidime and avibactam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with ≥ 99% reduction in parasitemia at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum level of PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hormone levels (testosterone, dihydrotestosterone, luteinizing hormone, sex hormone binding globulin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly severity of hair pulling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly severity of urge to pull
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily hair counts (or estimated hair pulled)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and safety of continuous infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor blockade level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal satisfaction with analgesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhibition of MAC-1 expression on neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total weaning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of manipulations on the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Variations in arterial partial pressure of carbon dioxide (PaCO2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in surgical management due to IOUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection of additional metastases by IOUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alteration of disease stage by IOUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: headache intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sit-and-reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBU scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KAT static and dynamic balance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically acceptable intubation conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: complete response rates to prophylactic antiemetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of very satisfied patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: antiemetic drug acquisition costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: improvement in endoscopic, scintigraphic and histological scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of recurrent ischemia
Endpoint domain: Mortality/survival
Primary endpoint: incidence of major amputation
Endpoint domain: Mortality/survival
Primary endpoint: Q-TWiST (quality-adjusted survival)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Non-oxidative glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of viral replication markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of serum aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings per ICU bed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in AI (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of high-sensitive C-reactive protein (mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of serum asymmetric dimethylarginine (micromol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of disease progression
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in serum E-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in ICAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in circulating lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visit completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes